Anzhelika Vorobyeva

1.4k total citations
73 papers, 1.0k citations indexed

About

Anzhelika Vorobyeva is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Anzhelika Vorobyeva has authored 73 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Radiology, Nuclear Medicine and Imaging, 47 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Anzhelika Vorobyeva's work include Monoclonal and Polyclonal Antibodies Research (61 papers), Radiopharmaceutical Chemistry and Applications (48 papers) and HER2/EGFR in Cancer Research (38 papers). Anzhelika Vorobyeva is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (61 papers), Radiopharmaceutical Chemistry and Applications (48 papers) and HER2/EGFR in Cancer Research (38 papers). Anzhelika Vorobyeva collaborates with scholars based in Sweden, Russia and Netherlands. Anzhelika Vorobyeva's co-authors include Vladimir Tolmachev, Anna Orlova, Javad Garousi, Bogdan Mitran, Sergey M. Deyev, Sara S. Rinne, Maryam Oroujeni, Mohamed Altai, Alexey Schulga and Tianqi Xu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biomaterials.

In The Last Decade

Anzhelika Vorobyeva

70 papers receiving 996 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anzhelika Vorobyeva Sweden	20	799	499	330	122	67	73	1.0k
Daniel Rosik Sweden	15	931 1.2×	459 0.9×	437 1.3×	90 0.7×	51 0.8×	17	1.1k
Helena Wållberg Sweden	18	859 1.1×	462 0.9×	305 0.9×	88 0.7×	57 0.9×	26	978
Mohamed Altai Sweden	23	1.1k 1.3×	580 1.2×	425 1.3×	151 1.2×	55 0.8×	42	1.3k
Hadis Honarvar Sweden	20	698 0.9×	404 0.8×	309 0.9×	96 0.8×	37 0.6×	30	861
Bogdan Mitran Sweden	25	1.1k 1.4×	688 1.4×	370 1.1×	263 2.2×	57 0.9×	55	1.3k
Vania Kenanova United States	15	675 0.8×	271 0.5×	360 1.1×	78 0.6×	57 0.9×	20	862
Erasmus Poku United States	14	419 0.5×	302 0.6×	156 0.5×	97 0.8×	107 1.6×	33	660
Huiyun Zhao China	19	458 0.6×	263 0.5×	254 0.8×	124 1.0×	151 2.3×	38	894
Conrad Chan Canada	16	504 0.6×	261 0.5×	213 0.6×	158 1.3×	82 1.2×	32	772
Dietmar Berndorff Germany	14	548 0.7×	326 0.7×	538 1.6×	76 0.6×	47 0.7×	18	1.0k

Countries citing papers authored by Anzhelika Vorobyeva

Since Specialization

Citations

This map shows the geographic impact of Anzhelika Vorobyeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anzhelika Vorobyeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anzhelika Vorobyeva more than expected).

Fields of papers citing papers by Anzhelika Vorobyeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anzhelika Vorobyeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anzhelika Vorobyeva. The network helps show where Anzhelika Vorobyeva may publish in the future.

Co-authorship network of co-authors of Anzhelika Vorobyeva

This figure shows the co-authorship network connecting the top 25 collaborators of Anzhelika Vorobyeva. A scholar is included among the top collaborators of Anzhelika Vorobyeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anzhelika Vorobyeva. Anzhelika Vorobyeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolmachev, Vladimir, Anzhelika Vorobyeva, Javad Garousi, et al.. (2025). Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture. International Journal of Molecular Sciences. 26(11). 5236–5236. 1 indexed citations

Zhang, Jie, Sara S. Rinne, E. Bjorklund, et al.. (2024). Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts. ACS Pharmacology & Translational Science. 7(10). 3228–3240. 2 indexed citations

Xu, Tianqi, et al.. (2023). Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab. Cancers. 15(9). 2409–2409. 13 indexed citations

Xu, Tianqi, Jie Zhang, М. В. Белоусов, et al.. (2023). Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. Journal of Controlled Release. 355. 515–527. 11 indexed citations

Xu, Tianqi, Alexey Schulga, Е. В. Коновалова, et al.. (2023). Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences. 24(3). 2838–2838. 3 indexed citations

Garousi, Javad, Tianqi Xu, Olga Vorontsova, et al.. (2022). Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics. 14(8). 1612–1612. 3 indexed citations

Rinne, Sara S., Ayman Abouzayed, Anzhelika Vorobyeva, et al.. (2022). Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. Biomedicines. 10(6). 1293–1293. 5 indexed citations

Plotnikov, Evgenii, Roman Zelchan, Alexey Schulga, et al.. (2022). Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer. International Journal of Molecular Sciences. 23(21). 13443–13443. 4 indexed citations

Xu, Tianqi, Jie Zhang, Maryam Oroujeni, et al.. (2022). Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. Pharmaceutics. 14(3). 522–522. 7 indexed citations

10.

Xu, Tianqi, Anna Orlova, Maryam Oroujeni, et al.. (2022). Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics. 14(7). 1475–1475. 7 indexed citations

11.

Vorobyeva, Anzhelika, Leendert J. van den Bos, Robert Naasz, et al.. (2022). Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics. 14(11). 2519–2519. 5 indexed citations

12.

Tolmachev, Vladimir, Maryam Oroujeni, Sergey M. Deyev, et al.. (2022). Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy. International Journal of Molecular Sciences. 23(23). 15181–15181. 5 indexed citations

13.

Xu, Tianqi, Anzhelika Vorobyeva, Alexey Schulga, et al.. (2021). Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. Cancers. 13(16). 3939–3939. 11 indexed citations

14.

Xu, Tianqi, Maryam Oroujeni, Jie Zhang, et al.. (2021). The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics. 13(11). 1974–1974. 11 indexed citations

15.

Garousi, Javad, Tianqi Xu, Anzhelika Vorobyeva, et al.. (2021). Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 13(11). 1847–1847. 8 indexed citations

16.

Xu, Tianqi, Jie Zhang, Vladimir Tolmachev, et al.. (2021). Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics. 13(3). 430–430. 14 indexed citations

17.

Deyev, Sergey M., Tianqi Xu, Alexey Schulga, et al.. (2021). Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. Cancers. 13(14). 3589–3589. 12 indexed citations

18.

Xu, Tianqi, Anzhelika Vorobyeva, Maryam Oroujeni, et al.. (2020). Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers. 13(1). 85–85. 25 indexed citations

19.

Vorobyeva, Anzhelika, Е. В. Коновалова, Bogdan Mitran, et al.. (2019). Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. International Journal of Oncology. 54(4). 1209–1220. 27 indexed citations

20.

Garousi, Javad, Sarah Lindbo, Anzhelika Vorobyeva, et al.. (2019). Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. European Journal of Pharmaceutics and Biopharmaceutics. 140. 109–120. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact